SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 14, 2018

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2029

Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
DRUG

Pembrolizumab

Anti-PD-1 targeted immunotherapy

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

High-precision radiotherapy

Trial Locations (21)

11042

RECRUITING

Northwell Health, Lake Success

15232

RECRUITING

University of Pittsburgh Medical Center Shadyside, Pittsburgh

17033

RECRUITING

Penn State Milton S. Hershey Medical Center, Hershey

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

33331

RECRUITING

Cleveland Clinic - Weston, Weston

33612

RECRUITING

Moffitt Cancer Center, Tampa

40202

RECRUITING

University of Louisville, James Graham Brown Cancer Center, Louisville

43210

RECRUITING

Ohio State University, Columbus

44106

WITHDRAWN

University Hospitals Cleveland Medical Center, Cleveland

44195

RECRUITING

Cleveland Clinic, Cleveland

45219

RECRUITING

University of Cincinnati Cancer Center - UC Medical Center, Cincinnati

48202

WITHDRAWN

Henry Ford Hospital, Detroit

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

63110

RECRUITING

Washington University St. Louis, St Louis

75390

COMPLETED

University of Texas Southwestern, Dallas

85719

RECRUITING

University of Arizona Cancer Center - North Campus, Tucson

02118

RECRUITING

Boston Medical Center, Boston

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

H2X 3E4

RECRUITING

Centre Hospitalier de l'université de Montréal, Montreal

H4A 3J1

RECRUITING

McGill University, Montreal

G1R 2J6

WITHDRAWN

CHU de Quebec - Universite Laval, Québec

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

RTOG Foundation, Inc.

OTHER